MedPath

Effectiveness of Endocuff Vision in Improving ADR

Completed
Conditions
Colorectal Neoplasms
Interventions
Device: Endocuff Vision (ECV)
Registration Number
NCT04395352
Lead Sponsor
University of Calgary
Brief Summary

The goal of distal attachment devices is to enhance an endoscopist's adenoma detection rate (ADR). A device called EndoCuff Vision (ECV) has been introduced that employs a single row of flexible arms to evert colonic folds, thus optimizing mucosal visualization and enhancing ADR. ECV has been shown to be efficacious in improving ADR within the context of randomized trials. However, no 'real-world' studies have been published assessing the effectiveness of ECV in non-trial settings. The primary objective of this study is to assess the effect of ECV use on ADR in a routine screening-related population.

Detailed Description

Not available

Recruitment & Eligibility

Status
COMPLETED
Sex
All
Target Recruitment
15816
Inclusion Criteria

adult patients undergoing colonoscopy.

Read More
Exclusion Criteria
  • single balloon- or double balloon-assisted colonoscopy;
  • planned advanced polypectomy or endoscopic mucosal resection (EMR);
  • planned endoscopic post-polypectomy or post-EMR surveillance;
  • known active diverticulitis;
  • known colonic stricture.
Read More

Study & Design

Study Type
OBSERVATIONAL
Study Design
Not specified
Arm && Interventions
GroupInterventionDescription
ECVEndocuff Vision (ECV)Patients having undergone colonoscopy after the introduction of ECV (June 1 2019 to November 30 2019).
Primary Outcome Measures
NameTimeMethod
Adenoma detection rate (ADR)Intra-procedural

Proportion of an endoscopist's screening-related colonoscopies during which one or more adenoma was biopsied or removed

Secondary Outcome Measures
NameTimeMethod
Adenoma detection rate among patients with positive fecal immunochemical testsIntra-procedural

Proportion of an endoscopist's colonoscopies performed for +fecal immunochemical test (FIT), or indications other than positive FIT during which one or more adenoma was biopsied or removed. In order to be included in the non-FIT ADR category, a patient must not have undergone a colonoscopy at CCSC within the last four years of the index procedure.

Nurse-assessed patient comfort scores (NAPCOMs)Intra-procedural

Validated score for determining patients' procedural comfort. Scored from 0 to 9, with higher scores indicating higher discomfort intensity, frequency, and/or duration.

CIR (cecal intubation rate)Intra-procedural

Proportion of an endoscopist's screening-related procedures in which the cecal pole is intubated, as landmarked by direct visualization of the appendiceal orifice, ileocecal valve, or both.

Procedure timeIntra-procedural

Total time spent by an endoscopist from the start of the colonoscopy procedure (insertion of the colonoscope through the anus) to the end of the colonoscopy (removal of the colonoscope from the anus). This variable will be calculated only for cases in which no pathology was encountered.

Number of patients with immediate adverse eventsDay 1

Adverse events occurring at the time of colonoscopy or before discharge, including bleeding or perforation.

SSADR (sessile serrated adenoma detection rate)Intra-procedural

Proportion of an endoscopist's screening-related colonoscopies during which one or more sessile serrated adenoma was biopsied or removed

Number of patients with delayed adverse eventsWithin 30 days of index procedure

Adverse events within 30 days of the index procedure, including delayed bleeding, delayed perforation, or acute healthcare utilization (emergency department visit or hospital admission) for any other reasons deemed related to index colonoscopy.

Trial Locations

Locations (1)

Forzani and MacPhail Colon Cancer Screening Centre (CCSC)

🇨🇦

Calgary, Alberta, Canada

© Copyright 2025. All Rights Reserved by MedPath